Optimizing Myelofibrosis Management: Clinical Strategies, Treatment Innovations, and Financial Toxicity Considerations : Episode 2

Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

July 31, 2024

By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Opinion

Video

A clinical pharmacy manager discusses challenges frequently encountered in the treatment of patients with myelofibrosis.

EP: 1.Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

EP: 2.Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

EP: 3.Impact of Myelofibrosis on Quality of Life: Key Clinical Features

EP: 4.Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

EP: 5.JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

EP: 6.Key Patient Factors Guiding Myelofibrosis Treatment Selection

EP: 7.Key Outcomes for Monitoring Myelofibrosis Treatment Response

EP: 8.Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

EP: 9.Understanding Financial Toxicity in Myelofibrosis

EP: 10.Advancing Myelofibrosis Treatment: What Lies Ahead

EP: 11.K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following question:

What remains the biggest unmet need in terms of disease management?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.